secwatch / observer
8-K/A filed September 5, 2023, 7:59 PM ET CIK 0001499785
other material confidence high sentiment negative materiality 0.85

Tengjun Biotechnology Corp.: auditor change — Tengjun Biotechnology restates FY2022 financials; appoints Caihong Qu as interim CEO/CFO after CEO death

Tengjun Biotechnology Corp.

item 4.02item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Xianchang Ma

Director, Chief Executive Officer and Chief Financial Officer
Tengjun Biotechnology Corp.
Effective
2023-08-03
Successor
Caihong Qu
Filed
September 5, 2023, 7:59 PM ET
who passed away on August 3, 2023
Appointed

Caihong Qu

Member of the Board
Tengjun Biotechnology Corp.
Effective
2023-08-10
Filed
September 5, 2023, 7:59 PM ET
On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
Appointed (interim)

Caihong Qu

interim Chief Executive Officer and Chief Financial Officer
Tengjun Biotechnology Corp.
Effective
2023-08-10
Filed
September 5, 2023, 7:59 PM ET
On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

Tengjun Biotechnology Corp. reported that prior financial statements should not be relied upon.

Action
non reliance
Exact text from the filing
On August 10, 2023, Tengjun Biotechnology Corp. (the "Company") announced that its Board of Directors (the "Board") concluded that the Company's previously issued financial statements, contained within its Annual Report on Form 10-K for the fiscal year ended December 31, 2022, should no longer be relied upon due to accounting methodology errors in such financial statements and that the Board deems it advisable and in the best interests of the Company to restate the financial statements by amending its annual report on Form 10-K for the fiscal year ended December 31, 2022 as soon as reasonably practicable.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Xianchang Ma departed as Director, Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..

Action
passed away
Role
Director, Chief Executive Officer and Chief Financial Officer
Exact text from the filing
who passed away on August 3, 2023
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Caihong Qu was appointed as Member of the Board at Tengjun Biotechnology Corp..

Action
appointed
Role
Member of the Board
Exact text from the filing
On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Caihong Qu was appointed as interim Chief Executive Officer and Chief Financial Officer at Tengjun Biotechnology Corp..

Action
appointed
Role
interim Chief Executive Officer and Chief Financial Officer
Exact text from the filing
On August 10, 2023, the Board resolved to appoint Ms. Caihong Qu as a member of the Board and the interim Chief Executive Officer and Chief Financial Officer of the Company
View on SEC.gov

7 auditor changes filed in the last 30 days. Browse all auditor changes →

Source: SEC EDGAR
accession 0001213900-23-073763
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.